Castle Biosciences Is Maintained at Sector Outperform by Scotiabank
Castle Biosciences Analyst Ratings
Scotiabank Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $44
Strong Growth Prospects and Financial Health Support Buy Rating for Castle Biosciences
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $45
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $40
Castle Biosciences (CSTL) Gets a Buy From Lake Street
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $42
Baird Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $39
Castle Biosciences Is Maintained at Outperform by Baird
Castle Biosciences Analyst Ratings
KeyBanc Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $36
Castle Biosciences Is Maintained at Buy by Canaccord Genuity
Castle Biosciences Analyst Ratings
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $42
Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $34
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $40
Castle Biosciences' TissueCypher Gains Buy Rating Due to Market Potential and Medicare Reimbursement
Castle Biosciences Analyst Ratings
Castle Biosciences (CSTL) Receives a Buy From Scotiabank